Key Takeaways from the GPRC5D-directed Therapies Market Report<\/b><\/p>\n Discover which indication is expected to grab the major GPRC5D-directed therapies market share @ GPRC5D-directed Therapies Market Report<\/b><\/a><\/p>\n GPRC5D-directed Therapies Market Dynamics<\/b><\/p>\n The GPRC5D-directed therapies market is emerging as a significant focus within the landscape of multiple myeloma treatment. GPRC5D is an orphan receptor predominantly expressed on malignant plasma cells, with limited expression in normal tissues, making it an attractive therapeutic target. Its expression is independent of BCMA<\/b>, allowing it to serve as a complementary or alternative target, particularly in patients who have relapsed after BCMA-directed treatments. This has driven a wave of innovation in bispecific antibodies, ADCs, and CAR-T cell therapies targeting GPRC5D<\/b>.<\/p>\n The competitive landscape is rapidly evolving, with multiple biotech and pharmaceutical companies advancing GPRC5D-targeted candidates<\/b> through preclinical and clinical pipelines. Notably, companies such as Johnson & Johnson <\/b>(via its teclistamab platform) and Legend Biotech<\/b> are exploring GPRC5D-directed bispecifics and CAR-T constructs, respectively. Early-phase clinical trials have shown promising efficacy in relapsed\/refractory multiple myeloma (RRMM) populations<\/b>, even among those previously treated with BCMA-targeted agents. The ability of GPRC5D-targeting therapies to produce deep and durable responses<\/b>, with manageable toxicity profiles, is a key factor fueling investor interest and partnerships in this space.<\/p>\n Market dynamics are further shaped by the unmet clinical need in late-line multiple myeloma settings<\/b>. As more patients receive BCMA therapies earlier in their treatment journeys, resistance and relapse rates have prompted the search for alternative targets like GPRC5D. Regulatory agencies<\/b>, including the FDA and EMA, have shown openness to accelerated pathways<\/b> for novel immunotherapies in RRMM, creating favorable conditions for GPRC5D-focused assets. Additionally, the ongoing development of allogeneic platforms and off-the-shelf bispecific antibodies<\/b> is poised to enhance patient access and reduce logistical burdens compared to autologous CAR-T approaches.<\/p>\n However, challenges remain in this emerging space. Differentiation among therapies targeting the same antigen<\/b> will be crucial, as companies aim to optimize dosing schedules, minimize on-target off-tumor toxicities, and address manufacturing scalability. Pricing and reimbursement strategies<\/b> will also play a critical role, particularly as competition intensifies and cost-effectiveness<\/b> comes under scrutiny from payers and health systems.<\/p>\n Looking forward, the GPRC5D-directed therapy market is expected to expand significantly over the next 10 years, driven by a combination of clinical validation, rising relapse rates in existing treatment paradigms, and an influx of new therapeutic modalities<\/b>. Success in this domain will likely depend on the ability to integrate GPRC5D-targeted agents<\/b> into combination regimens, leverage companion diagnostics to optimize patient selection, and establish long-term safety and efficacy through robust Phase III trials and real-world evidence.<\/p>\n GPRC5D-directed Therapies Treatment Market\u00a0<\/b><\/p>\n GPRC5D is highly expressed in multiple myeloma cells and is found in abundance within the bone marrow of patients diagnosed with multiple myeloma or smoldering multiple myeloma. Currently, TALVEY (talquetamab-tgvs)<\/b>, approved in August 2023, is the first and the only approved GPRC5D-directed therapy in the market. TALVEY is a novel, first-in-class bispecific T-cell engager that simultaneously binds to the CD3 receptor on T cells and GPRC5D, which is present on multiple myeloma cells, non-cancerous plasma cells, and certain healthy epithelial tissues, particularly in the skin and tongue. It is administered subcutaneously on a weekly or biweekly basis following an initial step-up dosing phase, giving physicians the flexibility to tailor dosing schedules to individual patient needs.<\/p>\n Learn more about the FDA-approved GPRC5D-directed therapies\u00a0@ Approved <\/b>GPRC5D-directed Therapies\u00a0<\/b><\/a><\/p>\n Key Emerging GPRC5D-directed Therapies and Companies<\/b><\/p>\n Some of the major emerging key players in the GPRC5D market include CARsgen Therapeutics<\/b> (CT071), Oricell <\/b>(OriCAR-017), Bristol-Myers Squibb<\/b> (Arlocabtagene autoleucel), AstraZeneca <\/b>(AZD0305), and others.<\/p>\n OriCAR-017<\/b>\u00a0is an innovative CAR T cell therapy developed to target GPRC5D, aimed at treating relapsed or refractory multiple myeloma. Developed using Oricell Therapeutics’ advanced proprietary technology, OriCAR-017 demonstrates unique advantages in terms of binding strength, cell persistence, tumor-fighting capability, and safety. It received Investigational New Drug (IND) approval from the U.S. FDA in January 2024, following earlier approval by China’s NMPA in 2023.<\/p>\n BMS-986393<\/b>\u00a0is an autologous CAR T cell therapy also directed at GPRC5D. Currently under evaluation in the Phase II QUINTESSENTIAL trial for relapsed\/refractory multiple myeloma, the therapy is expected to yield key data in 2026. At the ASH 2023 conference, updated results from its Phase I trial highlighted durable responses, manageable safety, and clinical activity in patients regardless of prior BCMA-targeted treatment exposure.<\/p>\n The anticipated launch of these emerging therapies are poised to transform the GPRC5D-directed therapies\u00a0market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the GPRC5D-directed therapies\u00a0market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.<\/p>\n To know more about GPRC5D-directed therapies\u00a0clinical trials, visit @ GPRC5D-directed Therapies Treatment\u00a0<\/b><\/a><\/p>\n GPRC5D-directed Therapies Overview<\/b><\/p>\n GPRC5D, an orphan G-protein-coupled receptor located on chromosome 12p13, lacks a known ligand. It has emerged as a validated therapeutic target in multiple myeloma. Early-phase clinical trials involving T\u2013cell\u2013reducing therapies aimed at GPRC5D have demonstrated encouraging efficacy along with tolerable safety profiles, although these findings still require confirmation in Phase III studies.<\/p>\n This receptor is highly expressed in multiple myeloma cells and is prevalent in the bone marrow of patients with both active and smoldering disease. Furthermore, its mRNA levels are notably higher in multiple myeloma compared to other hematologic malignancies. The selective overexpression of GPRC5D in myeloma cells makes it an attractive candidate for immune effector cell\u2013based therapies. Targeting GPRC5D, either as a standalone treatment or in combination with other anti-myeloma agents, could broaden the therapeutic landscape, particularly for patients who require novel mechanisms of action, whether to delay the use of BCMA-targeted therapies, overcome poor responses or antigen loss, or address clonal variability.<\/p>\n Although GPRC5D and BCMA are both expressed on CD138+ myeloma cells, their expression is not interdependent, making them distinct therapeutic targets. Importantly, GPRC5D expression remains stable even when BCMA is lost, a known resistance mechanism in some relapsed patients, supporting the rationale for combining GPRC5D- and BCMA-directed T-cell therapies to better manage the disease’s heterogeneity.<\/p>\n GPRC5D-directed Therapies Epidemiology Segmentation<\/b><\/p>\n The GPRC5D-directed therapies market report proffers epidemiological analysis for the study period 2020\u20132034 in the 7MM, segmented into:<\/p>\n GPRC5D-directed Therapies Report Metrics<\/b><\/p>\n<\/td>\n Details<\/b><\/p>\n<\/td>\n<\/tr>\n Study Period<\/p>\n<\/td>\n 2020\u20132034<\/p>\n<\/td>\n<\/tr>\n GPRC5D-directed Therapies Report\u00a0Coverage<\/p>\n<\/td>\n 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]<\/p>\n<\/td>\n<\/tr>\n Key GPRC5D-directed Therapies Companies<\/p>\n<\/td>\n Bristol Myers Squibb (Juno Therapeutics), AstraZeneca, Oricell, CARsgen Therapeutics, Sanofi, Jiangsu Simcere Pharmaceutical, AbbVie, Johnson & Johnson Innovative Medicine (Janssen Biotech), and others<\/p>\n<\/td>\n<\/tr>\n Key GPRC5D-directed Therapies<\/p>\n<\/td>\n Arlocabtagene autoleucel (BMS-986393), AZD0305, OriCAR-017, CT071, SAR446523, SIM0500, TALVEY, and others<\/p>\n<\/td>\n<\/tr>\n Scope of the <\/b>GPRC5D-directed Therapies<\/b>\u00a0Market Report<\/b><\/p>\n Discover more about GPRC5D-directed therapies in development @ GPRC5D-directed Therapies Clinical Trials<\/b><\/a><\/p>\n Table of Contents<\/b><\/p>\n 1.<\/p>\n<\/td>\n Key Insights<\/p>\n<\/td>\n<\/tr>\n 2.<\/p>\n<\/td>\n Report Introduction<\/p>\n<\/td>\n<\/tr>\n 3.<\/p>\n<\/td>\n Executive Summary<\/p>\n<\/td>\n<\/tr>\n 4.<\/p>\n<\/td>\n Key Events<\/p>\n<\/td>\n<\/tr>\n 5.<\/p>\n<\/td>\n Market Forecast Methodology<\/p>\n<\/td>\n<\/tr>\n 6.<\/p>\n<\/td>\n GPRC5D-directed Therapies Market Overview at a Glance in the 7MM<\/p>\n<\/td>\n<\/tr>\n 6.1.<\/p>\n<\/td>\n Market Share (%) Distribution by Therapies in 2025<\/p>\n<\/td>\n<\/tr>\n 6.2.<\/p>\n<\/td>\n Market Share (%) Distribution by Therapies in 2034<\/p>\n<\/td>\n<\/tr>\n 6.3.<\/p>\n<\/td>\n Market Share (%) Distribution by Indications in 2025<\/p>\n<\/td>\n<\/tr>\n 6.4.<\/p>\n<\/td>\n Market Share (%) Distribution by Indications in 2034<\/p>\n<\/td>\n<\/tr>\n 7.<\/p>\n<\/td>\n GPRC5D-directed Therapies: Background and Overview<\/p>\n<\/td>\n<\/tr>\n 7.1.<\/p>\n<\/td>\n Introduction<\/p>\n<\/td>\n<\/tr>\n 7.2.<\/p>\n<\/td>\n The Potential of GPRC5D-directed Therapies in Different Indications<\/p>\n<\/td>\n<\/tr>\n 7.3.<\/p>\n<\/td>\n Clinical Applications of GPRC5D-directed Therapies<\/p>\n<\/td>\n<\/tr>\n 8.<\/p>\n<\/td>\n Target Patient Pool of GPRC5D-directed Therapies<\/p>\n<\/td>\n<\/tr>\n 8.1.<\/p>\n<\/td>\n Assumptions and Rationale<\/p>\n<\/td>\n<\/tr>\n 8.2.<\/p>\n<\/td>\n Key Findings<\/p>\n<\/td>\n<\/tr>\n 8.3.<\/p>\n<\/td>\n Total Cases of Selected Indication for GPRC5D-directed Therapies in the 7MM<\/p>\n<\/td>\n<\/tr>\n 8.4.<\/p>\n<\/td>\n Total Eligible Patient Pool of Selected Indication for GPRC5D-directed Therapies in the 7MM<\/p>\n<\/td>\n<\/tr>\n 8.5.<\/p>\n<\/td>\n Total Treatable Cases in Selected Indication for GPRC5D-directed Therapies in the 7MM<\/p>\n<\/td>\n<\/tr>\n 9.<\/p>\n<\/td>\n Marketed Therapies<\/p>\n<\/td>\n<\/tr>\n 9.1.<\/p>\n<\/td>\n Key Competitors<\/p>\n<\/td>\n<\/tr>\n 9.2.<\/p>\n<\/td>\n TALVEY (talquetamab-tgvs): Johnson & Johnson Innovative Medicine<\/p>\n<\/td>\n<\/tr>\n 9.2.1.<\/p>\n<\/td>\n Product Description<\/p>\n<\/td>\n<\/tr>\n 9.2.2.<\/p>\n<\/td>\n Regulatory milestones<\/p>\n<\/td>\n<\/tr>\n 9.2.3.<\/p>\n<\/td>\n Other developmental activities<\/p>\n<\/td>\n<\/tr>\n 9.2.4.<\/p>\n<\/td>\n Clinical development<\/p>\n<\/td>\n<\/tr>\n 9.2.5.<\/p>\n<\/td>\n Safety and efficacy<\/p>\n<\/td>\n<\/tr>\n List to be continued in the report<\/p>\n<\/td>\n<\/tr>\n 10.<\/p>\n<\/td>\n Emerging Therapies<\/p>\n<\/td>\n<\/tr>\n 10.1.<\/p>\n<\/td>\n Key Competitors<\/p>\n<\/td>\n<\/tr>\n 10.2.<\/p>\n<\/td>\n OriCAR-017: Oricell<\/p>\n<\/td>\n<\/tr>\n 10.2.1.<\/p>\n<\/td>\n Product Description<\/p>\n<\/td>\n<\/tr>\n 10.2.2.<\/p>\n<\/td>\n Other developmental activities<\/p>\n<\/td>\n<\/tr>\n 10.2.3.<\/p>\n<\/td>\n Clinical development<\/p>\n<\/td>\n<\/tr>\n 10.2.4.<\/p>\n<\/td>\n Safety and efficacy<\/p>\n<\/td>\n<\/tr>\n 10.3.<\/p>\n<\/td>\n Arlocabtagene autoleucel (BMS-986393): Bristol Myers Squibb (Juno Therapeutics)<\/p>\n<\/td>\n<\/tr>\n 10.3.1.<\/p>\n<\/td>\n Product Description<\/p>\n<\/td>\n<\/tr>\n 10.3.2.<\/p>\n<\/td>\n Other developmental activities<\/p>\n<\/td>\n<\/tr>\n 10.3.3.<\/p>\n<\/td>\n Clinical development<\/p>\n<\/td>\n<\/tr>\n 10.3.4.<\/p>\n<\/td>\n Safety and efficacy<\/p>\n<\/td>\n<\/tr>\n List to be continued in the report<\/p>\n<\/td>\n<\/tr>\n 11.<\/p>\n<\/td>\n GPRC5D-directed Therapies: Seven Major Market Analysis<\/p>\n<\/td>\n<\/tr>\n 11.1.<\/p>\n<\/td>\n Key Findings<\/p>\n<\/td>\n<\/tr>\n 11.2.<\/p>\n<\/td>\n Market Outlook<\/p>\n<\/td>\n<\/tr>\n 11.3.<\/p>\n<\/td>\n Conjoint Analysis<\/p>\n<\/td>\n<\/tr>\n 11.4.<\/p>\n<\/td>\n Key Market Forecast Assumptions<\/p>\n<\/td>\n<\/tr>\n 11.4.1.<\/p>\n<\/td>\n Cost Assumptions and Rebates<\/p>\n<\/td>\n<\/tr>\n 11.4.2.<\/p>\n<\/td>\n Pricing Trends<\/p>\n<\/td>\n<\/tr>\n 11.4.3.<\/p>\n<\/td>\n Analogue Assessment<\/p>\n<\/td>\n<\/tr>\n 11.4.4.<\/p>\n<\/td>\n Launch Year and Therapy Uptakes<\/p>\n<\/td>\n<\/tr>\n 11.5.<\/p>\n<\/td>\n Total Market Sizes of GPRC5D-directed Therapies by Indications in the 7MM<\/p>\n<\/td>\n<\/tr>\n 11.6.<\/p>\n<\/td>\n The United States Market Size<\/p>\n<\/td>\n<\/tr>\n 11.6.1.<\/p>\n<\/td>\n Total Market Size of GPRC5D-directed Therapies in the United States<\/p>\n<\/td>\n<\/tr>\n 11.6.2.<\/p>\n<\/td>\n Market Size of GPRC5D-directed Therapies by Indication in the United States<\/p>\n<\/td>\n<\/tr>\n 11.6.3.<\/p>\n<\/td>\n Market Size of GPRC5D-directed Therapies by Therapies in the United States<\/p>\n<\/td>\n<\/tr>\n 11.7.<\/p>\n<\/td>\n EU4 and the UK\u00a0<\/p>\n<\/td>\n<\/tr>\n 11.7.1.<\/p>\n<\/td>\n Total Market Size of GPRC5D-directed Therapies in EU4 and the UK<\/p>\n<\/td>\n<\/tr>\n 11.7.2.<\/p>\n<\/td>\n Market Size of GPRC5D-directed Therapies by Indications in EU4 and the UK<\/p>\n<\/td>\n<\/tr>\n 11.7.3.<\/p>\n<\/td>\n Market Size of GPRC5D-directed Therapies by Therapies in EU4 and the UK<\/p>\n<\/td>\n<\/tr>\n 11.8.<\/p>\n<\/td>\n Japan\u00a0<\/p>\n<\/td>\n<\/tr>\n 11.8.1.<\/p>\n<\/td>\n Total Market Size of GPRC5D-directed Therapies Inhibitors in Japan<\/p>\n<\/td>\n<\/tr>\n 11.8.2.<\/p>\n<\/td>\n Market Size of GPRC5D-directed Therapies by Indications in Japan<\/p>\n<\/td>\n<\/tr>\n 11.8.3.<\/p>\n<\/td>\n Market Size of GPRC5D-directed Therapies by Therapies in Japan<\/p>\n<\/td>\n<\/tr>\n 12.<\/p>\n<\/td>\n SWOT Analysis<\/p>\n<\/td>\n<\/tr>\n 13.<\/p>\n<\/td>\n KOL Views<\/p>\n<\/td>\n<\/tr>\n 14.<\/p>\n<\/td>\n Unmet Needs<\/p>\n<\/td>\n<\/tr>\n 15.<\/p>\n<\/td>\n Market Access and Reimbursement<\/p>\n<\/td>\n<\/tr>\n 16.<\/p>\n<\/td>\n Appendix<\/p>\n<\/td>\n<\/tr>\n 16.1.<\/p>\n<\/td>\n Bibliography<\/p>\n<\/td>\n<\/tr>\n 16.2.<\/p>\n<\/td>\n Report Methodology<\/p>\n<\/td>\n<\/tr>\n 17.<\/p>\n<\/td>\n DelveInsight Capabilities<\/p>\n<\/td>\n<\/tr>\n 18.<\/p>\n<\/td>\n Disclaimer<\/p>\n<\/td>\n<\/tr>\n 19.<\/p>\n<\/td>\n About DelveInsight<\/p>\n<\/td>\n<\/tr>\n Related Reports<\/b><\/p>\n Multiple Myeloma Market<\/b><\/a><\/p>\n Multiple Myeloma Market Insights, Epidemiology, and Market Forecast \u2013 2034 <\/b>report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple myeloma\u00a0companies, including Sanofi, Karyopharm Therapeutics, AbbVie, Takeda Pharmaceutical, Celgene, Bristol-Myers Squibb, RAPA Therapeutics, Pfizer, Array Biopharma, Cellectar Biosciences, BioLineRx, Celgene, Aduro Biotech, ExCellThera, Janssen Pharmaceutical, Precision BioSciences, Takeda, Glenmark (Ichnos Sciences SA), Poseida Therapeutics, Molecular Partners AG, Chipscreen Biosciences, AbbVie, Genentech (Roche), Janssen Biotech, Nanjing Legend Biotech, Merck Sharp & Dohme Corp.,<\/b> among others.<\/p>\n CAR-T Market<\/b><\/a><\/p>\n CAR-T Market Size, Target Population, Competitive Landscape & Market Forecast \u2013 2034 <\/b>report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key CAR-T\u00a0companies, including Gilead Sciences, Inc., Novartis AG, Caribou Biosciences, Inc., Aurora Biopharma, Bristol-Myers Squibb Company, CARsgenTherapeutics Co., Ltd, JW Therapeutics (Shanghai) Co., Ltd., Cartesian Therapeutics, Inc., Johnson & Johnson Services, Inc. (Janssen Global Services, LLC),<\/b> among others.<\/p>\n Antibody Drug Conjugates Market<\/b><\/a><\/p>\n Antibody Drug Conjugates Market Size, Target Population, Competitive Landscape & Market Forecast \u2013 2034 <\/b>report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key ADC\u00a0companies, including NBE-Therapeutics, ImmunoGen, Inc., Seagen Inc., ADC Therapeutics, Mythic Therapeutics, Sutro Biopharma, Merck KGaA, Sorrento Therapeutics, Inc., Peak Bio, Regeneron Pharmaceuticals, Asana BioSciences, Tanabe Research Laboratories USA, OBI Pharma, Sanofi, Navrogen, Inc.,<\/b> among others.<\/p>\n Bispecifics\/Trispecifics Market<\/b><\/a><\/p>\n Bispecifics\/Trispecifics Market Forecast and Competitive Landscape \u2013 2035 <\/b>report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key bispecifics\/trispecifics\u00a0companies, including Janssen, Amgen, Akeso, Zymeworks, Roche, IGM Biosciences, MacroGenics, Provention Bio, Jiangsu Alphamab Biopharmaceuticals, Sichuan Baili Pharmaceutical, Regeneron Pharmaceuticals, Boehringer Ingelheim,<\/b> among others.<\/p>\n About\u00a0DelveInsight<\/b><\/p>\n DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.\u00a0Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform\u00a0PharmDelve.<\/b><\/p>\n Contact Us<\/b><\/p>\n Shruti Thakur \u00a0\n
\n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
[email\u00a0protected]<\/a>
+14699457679<\/p>\n
![\"\"](\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=IO23617&Transmission_Id=202507031731PR_NEWS_USPR_____IO23617&DateId=20250703\")
<\/p>\n","protected":false},"excerpt":{"rendered":"The GPRC5D-directed therapies market is witnessing robust growth, driven by the high unmet need in relapsed\/refractory multiple myeloma.…\n","protected":false},"author":3,"featured_media":28217,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[64,24334,4629,135,67,132,68],"class_list":{"0":"post-36357","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-markets","8":"tag-business","9":"tag-delveinsight-business-research","10":"tag-llp","11":"tag-markets","12":"tag-united-states","13":"tag-unitedstates","14":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/114791500576564142","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/36357","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=36357"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/36357\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/28217"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=36357"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=36357"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=36357"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}